Avita Medical Ltd (RCEL), now known as Avita Therapeutics, Inc., is a global regenerative medicine company that specializes in the treatment of wounds and skin defects. This healthcare firm is publicly traded and is headquartered in Valencia, California. Founded in 2008, it has a market capitalisation of around $400 million.
The company conducts groundbreaking research and development within the field of regenerative medicine, primarily focusing on creating new treatments for burns, chronic wounds, and aesthetic indications. Avita Medical Ltd's innovation trajectory is fuelled by a resilient commitment to address unmet medical needs and enhance patient lives, leveraging its innovative technology platforms.
Avita's flagship product, Recell System, is a pioneering breakthrough that uses a small sample of the patient's own skin to create Spray-On Skin™ Cells to rehabilitate and improve the appearance of severe burns. Recell System's approval in many regions such as the U.S, Europe and Australia, reveals the product’s potential and the robustness of Avita's scientific research, this resulted in a notable market leading position.
Apart from its groundbreaking product, the company places great emphasis on clinical trials, launching numerous studies to further demonstrate and validate the efficacy of its Recell System. This commitment to robust scientific research not only reinforces the value proposition of its existing products but also paves the way for future innovations.
Moreover, Avita Medical's strong financial standing is reflective of its ability to efficiently use resources to drive growth. This continued financial strength, coupled with its rich pipeline of potential products, positions it well for future expansion.
Over the years, Avita Medical Ltd has evolved into a staunch player in the regenerative medicine industry. The success of the company is testament to its relentless pursuit of innovation, commitment to scientific research, and the ability to address gaps in patient care with novel solutions. Hence, it casts an optimistic outlook on the continued growth and expanding reach of Avita Medical Ltd in the field of regenerative medicine.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Several biotech stocks, including CareDx Inc. (CDNA), AVITA Medical Inc. (RCEL), Azenta Inc. (AZTA), and Hinge Health Inc. (HNGE), reached 52-week highs on October 2, 2026. This surge was primarily driven by positive key catalysts such as encouraging quarterly reports and significant revenue growth. The article highlights each company's recent performance, product offerings, and financial outlook that contributed to their stock's strong performance.
This article provides a stock update for AVITA Medical Inc (51KB.HM), showing its current trading price and a recent news headline. The stock was down 3.06% at close on October 7. A recent report from Simply Wall St. highlighted a fair value lift for AVITA Medical (RCEL) after PermeaDerm data and Q2 beat.
This article provides a liquidity mapping analysis for Avita Medical Inc. (NASDAQ: RCEL), highlighting strong sentiment across all horizons and compelling upside potential due to the absence of resistance levels above the current price. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis for support and resistance levels. The analysis suggests an overweight bias for RCEL.
Avita Medical Inc. (NASDAQ:RCEL) has received a "Moderate Buy" consensus rating from seven brokerages, with an average 12-month price target of $11.40. This rating is supported by five buy ratings, one hold, and one sell. The company recently reported strong quarterly revenues of $21.7 million, surpassing analyst estimates, and a narrower-than-expected adjusted loss per share, leading to several analysts raising their price targets.
This article provides an analysis of Avita Medical Inc. (RCEL) for precision trading, highlighting strong sentiment, a breakout, and no resistance levels above the current price. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis indicating strong signals across all horizons. The piece emphasizes institutional-grade analysis and real-time trading signals for subscribers.
BlackRock Inc. recently acquired 564,952 shares of Avita Medical Inc. (NASDAQ:RCEL), valued at approximately $2.33 million, giving it a 1.84% stake in the company. Institutional investors now collectively own 27.66% of Avita Medical, which recently surpassed quarterly revenue and EPS expectations. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $11.40.